Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned an average rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $27.90.

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 18th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. JPMorgan Chase & Co. upped their target price on Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, February 19th. Morgan Stanley upped their target price on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Finally, Leerink Partners upped their target price on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors have recently modified their holdings of ELAN. NewEdge Advisors LLC raised its position in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the period. SJS Investment Consulting Inc. grew its holdings in Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares in the last quarter. Huntington National Bank grew its holdings in Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after buying an additional 1,087 shares in the last quarter. Root Financial Partners LLC grew its holdings in Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after buying an additional 592 shares in the last quarter. Finally, Uniplan Investment Counsel Inc. bought a new stake in Elanco Animal Health during the fourth quarter worth $41,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Price Performance

Shares of ELAN opened at $26.21 on Thursday. Elanco Animal Health has a 52-week low of $10.75 and a 52-week high of $27.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. The business’s 50 day moving average price is $23.85 and its two-hundred day moving average price is $23.33. The firm has a market cap of $13.03 billion, a PE ratio of -54.60, a price-to-earnings-growth ratio of 2.93 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period in the prior year, the firm earned $0.37 earnings per share. Elanco Animal Health’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts anticipate that Elanco Animal Health will post 1.03 EPS for the current year.

More Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q1 results beat consensus — Elanco reported adjusted EPS $0.40 (vs. $0.34 est.) and revenue $1.37B, with healthy organic growth and improved adjusted EBITDA and margins, signaling operational momentum. Elanco Animal Health Reports First Quarter 2026 Results
• Positive Sentiment: Company raised FY?2026 guidance — revenue and adjusted EBITDA ranges were lifted and Elanco increased its innovation revenue target and improved its year?end net leverage target, which supports earnings durability and deleveraging expectations. Elanco Animal Health Reports First Quarter 2026 Results
• Positive Sentiment: Regulatory / product catalysts — emergency use authorizations for Negasunt Powder and Tanidil add near?term product momentum and support Elanco’s innovation story. Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum
• Neutral Sentiment: Analyst sentiment is supportive — the consensus/average analyst view is around a “Moderate Buy,” which helps underwrite the rally but leaves upside dependent on execution. Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Moderate Buy” by Analysts
• Neutral Sentiment: Management commentary — the earnings call transcript highlights product momentum and execution priorities; useful for detail but no new surprises beyond the press release. Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q2 EPS guide slightly under street estimate — Elanco set Q2 EPS at $0.250–$0.285 vs. a ~$0.29 consensus, creating a modest near?term headwind despite the stronger full?year outlook. Elanco Animal Health Reports First Quarter 2026 Results

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.